Boustani, Malaz A., Campbell, Noll L., Khan, Babar A., Abernathy, Greg, Zawahiri, Mohammed, Campbell, Tiffany, Tricker, Jason, Hui, Siu L., Buckley, John D., Perkins, Anthony J., Farber, Mark O., Callahan, Christopher M.

Background: Approximately 40% of hospitalized older adults have cognitive impairment (CI) and are more prone to hospital-acquired complications. The Institute of Medicine suggests using health information technology to improve the overall safety and quality of the health care system.; Objective: Evaluate the efficacy of a clinical decision support system (CDSS) to improve the quality of […]

Chien, Wai-Tong, Lee, Isabella Y. M.

Aim: This paper reports a study to examine the effectiveness of a 6-month dementia care programme for Chinese families living with and caring for a relative with dementia, compared with routine family support services in Hong Kong.; Background: Recognizing the adverse psychosocial health effects inherent in dementia care, different psychosocial interventions provided preliminary evidence of […]

Salloway, Stephen, Sperling, Reisa, Fox, Nick C., Blennow, Kaj, Klunk, William, Raskind, Murray, Sabbagh, Marwan, Honig, Lawrence S., Porsteinsson, Anton P., Ferris, Steven, Reichert, Marcel, Ketter, Nzeera, Nejadnik, Bijan, Guenzler, Volkmar, Miloslavsky, Maja, Wang, Daniel, Lu, Yuan, Lull, Julia, Tudor, Iulia Cristina, Liu, Enchi, Grundman, Michael, Yuen, Eric, Black, Ronald, Brashear, H. Robert

Background: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer’s disease.; Methods: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer’s disease–one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying […]

Romeo, R., Knapp, M., Hellier, J., Dewey, M., Ballard, C., Baldwin, R., Bentham, P., Burns, A., Fox, C., Holmes, C., Katona, C., Lawton, C., Lindesay, J., Livingston, G., McCrae, N., Moniz-Cook, E., Murray, J., Nurock, S., O'Brien, J., Poppe, M., Thomas, A., Walwyn, R., Wilson, K., Banerjee, S.

Background: Depression is a common and costly comorbidity in dementia. There are very few data on the cost-effectiveness of antidepressants for depression in dementia and their effects on carer outcomes.; Aims: To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia.; Method: A pragmatic, multicentre, randomised placebo-controlled trial with a […]

Knapp, M., King, D., Romeo, R., Schehl, B., Barber, J., Griffin, M., Rapaport, P., Livingston, D., Mummery, C., Walker, Z., Hoe, J., Sampson, E. L., Cooper, C., Livingston, G.

Objective: To assess whether the START (STrAtegies for RelatTives) intervention added to treatment as usual is cost effective compared with usual treatment alone.; Design: Cost effectiveness analysis nested within a pragmatic randomised controlled trial.; Setting: Three mental health and one neurological outpatient dementia service in London and Essex, UK.; Participants: Family carers of people with […]